110703-94-1 Usage
Originator
Alond,Pfizer
Uses
Antidiabetic; inhibitor (aldose reductase).
Manufacturing Process
A mixture of 2-methyl-5-trifluoromethylbenzothiazole (1 mole-equivalent), N-
bromosuccinimide (1 mole-equivalent), carbon tetrachloride (700 ml) and a
catalytic amount of benzoyl peroxide (0.2 g) was refluxed under irradiation by
an UV lamp for 14 hours. The reaction mixture was cooled to room
temperature, filtered to remove the precipitated succinimide and the filtrate
was evaporated to dryness. The resulting solid was chromatographed over
silica gel to obtain the 2-bromomethyl-5-trifluoromethyl-benzothiazole.
To a mixture of ethyl 4-oxo-3H-phthalazin-1-ylacetate (1 mole-equivalent) and
sodium hydride (50% w/w dispersion in mineral oil) in dimethylformamide
(150 ml) was added 2-bromomethyl-5-trifluoromethylbenzothiazole (1 mole-
equivalent) and the resulting mixture stirred at room temperature for 1 hour.
This reaction mixture was poured over ice-water (500 ml); sufficient 10% HCl
was added to adjust the pH to about 4.0 and the precipitated crude solid was
collected. This was chromatographed over silica gel to obtain the ethyl[4-oxo-
3-(5-trifluoromethylbenzothiazol-2-yl)-3,4-dihydro-phthalazin-1-yl]acetate;
MP: 134°-136°C.
A solution of methyl or ethyl [4-oxo-3-(5-trifluoromethylbenzothiazol-2-yl)-
3,4-dihydrophthalazin-1-yl]acetate (1 mole-equivalent) in methanol (50 ml)
Therapeutic Function
Aldose reductase inhibitor
Check Digit Verification of cas no
The CAS Registry Mumber 110703-94-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,0,7,0 and 3 respectively; the second part has 2 digits, 9 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 110703-94:
(8*1)+(7*1)+(6*0)+(5*7)+(4*0)+(3*3)+(2*9)+(1*4)=81
81 % 10 = 1
So 110703-94-1 is a valid CAS Registry Number.
InChI:InChI=1/C19H12F3N3O3S/c20-19(21,22)10-5-6-15-14(7-10)23-16(29-15)9-25-18(28)12-4-2-1-3-11(12)13(24-25)8-17(26)27/h1-7H,8-9H2,(H,26,27)
110703-94-1Relevant articles and documents
USE OF SUBSTITUTED 2 PHENYLBENZIMIDAZOLES AS MEDICAMENTS
-
, (2008/06/13)
The present invention relates to the use of a substituted 2-phenylbenzimidazole of formula I wherein R1, R2, R3, R 4, R5 and m have the meanings given in the claims, for the preparation of a medicament for the treatment or prevention of diseases involving glucagon receptors, as well as new compounds of formula I wherein R1 is a group of formula
